安康陕西石泉 医院剖腹产 要多少钱(安康照四维彩超的时间) (今日更新中)

SAN FRANCISCO, Dec. 2 (Xinhua) -- Only two weeks after its shipment, Amazon's Kindle Fire has already shown the momentum to grab the second place in global tablet computer market, research firm IHS predicted on Friday.Amazon is expected to ship 3.9 million Kindle Fire tablets during the last three months of 2011, the first quarter the product goes on sale, according to preliminary projection from IHS.The number will give Amazon a 13.8-percent share of global tablet market in the fourth quarter, surpassing the 4.8 percent held by No. 3 player Samsung, and second only to Apple's commanding 65.6 percent market share."Nearly two years after Apple Inc. rolled out the iPad, a competitor has finally developed an alternative which looks like it might have enough of Apple's secret sauce to succeed," Rhoda Alexander, senior manager of tablet and monitor research for IHS, said in a statement."Initial market response strongly suggests that Amazon, with the Kindle Fire, has found the right combination of savvy pricing, astute marketing, accessible content and an appropriate business model, positioning the Kindle Fire to appeal to a brand-new set of media tablet buyers," she added.IHS analysts noted that with a price tag of 199 U.S. dollars, the Kindle Fire has set a new bar for pricing, bringing the tablet within reach of a larger portion of the buying public.IHS expects Kindle Fire's rapid ascent to help fuel the expansion of the entire tablet market, now predicting that 64.7 million tablets will be shipped in 2011, higher than its previous forecast of 60 million issued in August.The total tablet shipment number this year will represent a 273- percent growth from 17.4 million units in 2010, said IHS, which has also increased its longer-term projection of global tablet shipment in 2015 to 287.2 million units.

WASHINGTON, Oct. 4 (Xinhua) -- Green tea may slow down weight gain and serve as another tool in the fight against obesity, according to U.S. Pennsylvania State University food scientists.Obese mice that were fed a compound found in green tea along with a high-fat diet gained weight significantly more slowly than a control group of mice that did not receive the green tea supplement, said Joshua Lambert, assistant professor of food science in agricultural sciences."In this experiment, we see the rate of body weight gain slows down," said Lambert.The researchers, who released their findings on Tuesday in the online version of Obesity, fed two groups of mice a high-fat diet. Mice that were fed Epigallocatechin-3-gallate -- EGCG -- a compound found in most green teas, along with a high-fat diet, gained weight 45 percent more slowly than the control group of mice eating the same diet without EGCG.In addition to lower weight gain, the mice fed the green tea supplement showed a nearly 30 percent increase in fecal lipids, suggesting that the EGCG was limiting fat absorption, according to Lambert. The green tea did not appear to suppress appetite. Both groups of mice were fed the same amount of high-fat food and could eat at any time."There seems to be two prongs to this," said Lambert. "First, EGCG reduces the ability to absorb fat and, second, it enhances the ability to use fat."A person would need to drink ten cups of green tea each day to match the amount of EGCG used in the study, according to Lambert. However, he said that recent studies indicate that just drinking a few cups of green tea may help control weight."Human data -- and there's not a lot at this point -- shows that tea drinkers who only consume one or more cups a day will see effects on body weight compared to nonconsumers," said Lambert.

CAPE TOWN, Nov. 13 (Xinhua) -- The research vessel SA Agulhas has set off from Cape Town on a 10-day polar tour intended to promote dialogue on climate change, authorities confirmed on Sunday.The trip was designed to mark the 17th Climate Conference of the Parties (COP17) to be held in Durban later this month, according to the Department of Environmental Affairs.The voyage, which set off Saturday noon with scientists, academics, students and journalists aboard, would host exhibitions, symposiums and lectures from climate change scientists on the work of the polar research vessel, spokesman Zolile Nqayi said in a statement.The exhibitions and lectures would also highlight the various scientific activities undertaken by the department and its partners in Antarctica and the Southern Oceans, according to the South African Press Association (SAPA).Apart from her research and supply work, the Agulhus also helped to rescue the Magdalena Oldendorff, which became stuck in thick ice in June 2002.In December the SA Agulhas would make its final voyage to Antarctica before retirement.The Agulhas, which has been in service for 33 years, would be replaced by a new vessel under construction in Finland."She served us very well," said Dr Monde Mayekiso, deputy director general of oceans and coasts."The new vessel will have enhanced technologies and capabilities to further understand the ocean environment and to bring that understanding to an increasing number of South Africans, " he said.

BEIJING, Oct. 28 (Xinhuanet) -- Taking aspirin everyday may lower the risk of developing colon cancer for people with the cancer-causing genes, researchers found.The finding was published on Friday in the British medical journal "Lancet".The researchers followed 508 patients with Lynch syndrome, an inherited disorder which increases the risk of developing colon and other cancers.These patients were divided into two groups: members in one group took 600 mg aspirins everyday; another group took only the dummy pills.After 4 years, 10 colon cancer cases were reported among 258 patients who took daily aspirins for at least two years, comparing with 23 cases among 250 patients on dummy pills."This is good news for a very specific population," said Asad Umar, a cancer prevention expert at the U.S. National Cancer Institute.However, the finding doesn't apply to the general public, suggested the lead author of the study John Burn, a geneticist at Newcastle University in England.Only those who are at risk of such diseases should consider taking aspirin regularly, such as people having a family history of colon cancer, he added.

WASHINGTON, Oct. 9 (Xinhua) -- U.S. researchers have found a way to block, in an animal model, the damaging inflammation that contributes to many disease conditions. In their report receiving early online publication Sunday in Nature Biotechnology, researchers describe using small interfering RNA technology to silence the biochemical signals that attract a particular group of inflammatory cells to areas of tissue damage."The white blood cells known as monocytes play a critical role in the early stages of the immune response," says Matthias Nahrendorf, of the Massachusetts General Hospital (MGH) Center for Systems Biology, the paper's senior author. "We now know there are two subsets of monocytes -- an inflammatory subset that defends against pathogens and a reparative subset that supports healing. But if the inflammatory response is excessive, it can block the healing process and exacerbate conditions such as heart disease and cancer."Cells damaged by injury or disease release a cocktail of chemicals called cytokines that attract immune cells to the site of the damage. Inflammatory monocytes are guided to sites of tissue injury by a receptor protein called CCR2, and the MGH-led team devised a strategy targeting that molecule to block the inflammatory process but not the action of the reparative monocytes.Small interfering RNA (siRNA) technology prevents production of specific proteins by binding to associated messenger RNA molecules and preventing their translation. However, the technique requires extreme precision in developing the right siRNA molecule and delivering it to the correct cellular location.To make sure that their siRNA preparation targeted the right monocytes, researchers first confirmed that its use reduced levels of CCR2 in monocytes and increased levels of the fragments produced when siRNA binds to its target. They then showed that monocytes from mice treated with the siRNA preparation were unable to migrate towards CCR2's usual molecular target. Experiments in animal models of several important diseases showed that the siRNA preparation reduced the amount of cardiac muscle damaged by a heart attack, reduced the size and the number of inflammatory cells in atherosclerotic plaques and in lymphomas, and improved the survival of transplanted pancreatic islets."These inflammatory monocytes are involved in almost every major disease," Nahrendorf explains. "Anti-inflammatory drugs currently on the market hit every inflammatory cell in the body, which can produce unwanted side effects. This new siRNA treatment doesn't affect inflammatory cells that don't rely on the CCR2 receptor. That makes a big difference."

来源：资阳报